Obsessive-Compulsive Disorder Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (SSRI, TCA ), By Application, By Region & Competition, 2020-2030F
강박장애 치료제 세계 시장 규모는 2024년에 8억 8,250만 달러로 평가되었으며, 2030년까지의 CAGR은 7.60%를 나타낼 것으로 예상됩니다. 강박성 장애(OCD)로 알려진 불안 신경증은 불합리하고 통제 할 수없는 사고와 우려로 특징 지어지고 반복적인 행동을 하게 되는 것이 특징입니다. 예를 들어, National Comorbidity Survey Replication에 따르면 미국 성인의 1.2%가 지난 1년간 OCD를 발병했으며, 남성(0.5%)에 비해 여성(1.8%)의 유병률이 높은 것이 특징입니다. 강박성 장애는 특정한 생각이나 공포에 고집해 버리는 증상입니다. 강박장애 치료제 시장은 항불안제, 항정신병제, 항우울제뿐만 아니라 최근의 치료법, 요법, 혁신적인 치료법의 개선으로 더욱 많은 전망이 예상되고 있습니다. 그러나 브랜드 의약품의 제네릭 의약품의 도입과 특허 의약품의 특허 만료이 예측 기간 동안 시장 발전을 방해하는 두 가지 요인이 되고 있습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
8억 8,250만 달러 |
| 시장 규모 : 2030년 |
13억 5,866만 달러 |
| CAGR : 2025-2030년 |
7.60% |
| 급성장 부문 |
선택적 세로토닌 재 흡수 억제제 |
| 최대 시장 |
북미 |
주요 시장 성장 촉진요인
강박성 장애의 유병률 증가
주요 시장 과제
병존 질환
주요 시장 동향
스티그마 감소
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 세계의 강박장애 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 유형별(SSRI(선택적 세로토닌 재흡수 억제제), TCA(삼환계 항우울제))
- 용도별(연구기관, 병원 및 진료소, 기타)
- 지역별
- 기업별(2024년)
- 시장 맵
제6장 아시아태평양의 강박장애 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 아시아태평양: 국가별 분석
제7장 유럽의 강박장애 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 유럽 : 국가별 분석
제8장 북미의 강박장애 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 북미: 국가별 분석
제9장 남미의 강박장애 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 강박장애 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 중동 및 아프리카: 국가별 분석
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 강박장애 치료제 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
- 업계 내 경쟁
- 신규 진입의 가능성
- 공급자의 힘
- 고객의 힘
- 대체품의 위협
제15장 PESTEL 분석
제16장 경쟁 구도
- Abbott SA
- Eli Lilly, and Company
- Viatria Inc.,
- H. LUNDBECK A/S
- GlaxoSmithKline plc
- Pfizer Inc.
- Zydus Pharmaceuticals, Inc.
- Lupin Pharmaceuticals, Inc.,
- Amneal Pharmaceuticals LLC.
- Teva Pharmaceutical industries Ltd.
제17장 전략적 제안
제18장 기업 소개와 면책사항
SHW
Global Obsessive-Compulsive Disorder Drugs Market was valued at USD 882.50 million in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.60% through 2030. An anxiety illness known as obsessive-compulsive disorder (OCD) is characterized by irrational and uncontrolled thoughts and concerns that drive a person to engage in repetitive behavior. For instance, according to the National Comorbidity Survey Replication, 1.2% of U.S. adults had OCD in the past year, with a higher prevalence in females (1.8%) compared to males (0.5%). Obsessive-compulsive disorder is a condition that causes a person to get fixated on a certain idea or fear. Numerous further prospects in the market for OCD medications are anticipated to arise because of recent improvements in therapy, therapies, and innovative treatments as well as in anti-anxiety, antipsychotic, and antidepressant medications. However, the introduction of generic versions of branded medications and the patent expiration of patented ones are two factors anticipated to impede market development over the projection period.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 882.50 Million |
| Market Size 2030 | USD 1358.66 Million |
| CAGR 2025-2030 | 7.60% |
| Fastest Growing Segment | Selective Serotonin Reuptake Inhibitors |
| Largest Market | North America |
Key Market Drivers
Increasing Prevalence of OCD
Increased awareness campaigns, both online and offline, have educated the public and healthcare professionals about the symptoms of OCD. As people become more informed, they are more likely to seek help and receive a diagnosis. For instance, according to a January 2022 research article, fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) approved for obsessive-compulsive disorder, has shown potential therapeutic benefits for COVID-19 based on multiple studies. This highlights its emerging role beyond mental health treatment.
Additionally, according to WHO data updated in September 2021, depression affects approximately 5% of adults globally and is the leading cause of disability worldwide. This high prevalence drives demand for antidepressants, significantly contributing to market growth as more individuals seek effective treatment options.
Advances in the understanding of OCD have led to more precise diagnostic criteria. This has enabled healthcare providers to identify OCD in individuals who might have previously been misdiagnosed or undiagnosed. Efforts to reduce the stigma associated with mental health conditions have been ongoing. As stigma decreases, individuals are more willing to talk openly about their symptoms and seek treatment without fear of discrimination. In some healthcare settings, routine mental health screenings are becoming more common. This proactive approach can lead to the identification of individuals with OCD who may not have sought help otherwise. OCD often co-occurs with other mental health disorders, such as depression and anxiety. As these comorbid conditions are better recognized and treated, individuals with OCD may also receive a diagnosis and appropriate treatment. Events such as the COVID-19 pandemic have drawn attention to mental health issues, including OCD. The pandemic's impact on mental health has led to increased recognition of OCD symptoms in affected individuals.
Key Market Challenges
Comorbid Conditions
Individuals with comorbid conditions often require more complex treatment plans. When OCD is accompanied by other psychiatric disorders like depression, anxiety, or substance abuse, healthcare providers need to consider how these conditions interact and choose medications that can effectively address multiple symptoms. This complexity can lead to challenges in finding the right combination of drugs. Polypharmacy, the use of multiple medications concurrently, may be necessary for individuals with comorbid conditions. This can increase the risk of drug interactions, adverse effects, and medication non-adherence. Healthcare providers must carefully manage medication regimens to optimize treatment outcomes. Comorbid conditions can lead to variations in treatment responses. What works well for one condition may not be as effective for another. Finding medications that are both safe and effective across multiple conditions can be a challenge. Treating individuals with comorbid conditions often involves more frequent healthcare visits, medication management, and therapy sessions. These increased healthcare costs can impact both individuals and healthcare systems, potentially affecting the demand for OCD drugs. The presence of comorbid conditions can complicate the diagnostic process. Symptoms of one condition may mask or mimic those of another, leading to potential misdiagnoses. Accurate diagnosis is essential for tailoring treatment plans. In cases of comorbidity, healthcare providers must prioritize which condition to address first. For example, if a patient has both OCD and a substance use disorder, it may be necessary to treat the substance use disorder before addressing the OCD symptoms effectively.
Key Market Trends
Stigma Reduction
Reduced stigma encourages earlier intervention, which can lead to better treatment outcomes. When individuals seek help at the onset of symptoms, their conditions may be more manageable, potentially reducing the overall duration of treatment and the need for more intensive interventions. Stigma can be a barrier to medication adherence. When individuals are more open about their mental health conditions and receive support from their social networks, they may be more likely to adhere to their treatment plans, including taking prescribed OCD medications consistently. Stigma reduction efforts can lead to increased support for mental health services, including access to psychiatrists, therapists, and medication management. This expansion of services benefits individuals seeking treatment for OCD. When individuals with OCD feel less stigmatized, they may become more empowered to actively participate in their treatment decisions. This can lead to more collaborative and effective treatment plans, including medication choices. Stigma reduction often goes hand in hand with advocacy and support efforts. Patient advocacy groups and mental health organizations play a crucial role in raising awareness, destigmatizing mental health conditions, and advocating for improved access to mental health services and treatments. As stigma diminishes, there is a greater opportunity for the integration of mental health services into primary care settings. This can improve the identification and management of mental health conditions like OCD, potentially leading to more individuals receiving treatment.
Key Market Players
- Abbott SA
- Eli Lilly, and Company
- Viatria Inc.
- H. LUNDBECK A/S,
- GlaxoSmithKline plc
- Pfizer Inc.
- Zydus Pharmaceuticals, Inc.
- Lupin Pharmaceuticals, Inc.
- Amneal Pharmaceuticals LLC
- Teva Pharmaceutical industries Ltd.
Report Scope:
In this report, the Global Obsessive-Compulsive Disorder Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Obsessive-Compulsive Disorder Drugs Market, By Type:
- SSRI (Selective Serotonin Reuptake Inhibitors)
- TCA (Tricyclic Antidepressant)
Obsessive-Compulsive Disorder Drugs Market, By Application:
- Research Institute
- Hospitals & Clinics
- Others
Obsessive-Compulsive Disorder Drugs Market, By region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
- Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Obsessive-Compulsive Disorder Drugs Market.
Available Customizations:
Global Obsessive-Compulsive Disorder Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Obsessive-Compulsive Disorder Drugs Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Type (SSRI (Selective Serotonin Reuptake Inhibitors), TCA (Tricyclic Antidepressant))
- 5.2.2. By Application (Research Institute, Hospitals & Clinics, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
- 5.3. Market Map
6. Asia Pacific Obsessive-Compulsive Disorder Drugs Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Application
- 6.2.3. By Country
- 6.3. Asia Pacific: Country Analysis
- 6.3.1. China Obsessive-Compulsive Disorder Drugs Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Type
- 6.3.1.2.2. By Application
- 6.3.2. India Obsessive-Compulsive Disorder Drugs Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Type
- 6.3.2.2.2. By Application
- 6.3.3. Australia Obsessive-Compulsive Disorder Drugs Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Type
- 6.3.3.2.2. By Application
- 6.3.4. Japan Obsessive-Compulsive Disorder Drugs Market Outlook
- 6.3.4.1. Market Size & Forecast
- 6.3.4.2. Market Share & Forecast
- 6.3.4.2.1. By Type
- 6.3.4.2.2. By Application
- 6.3.5. South Korea Obsessive-Compulsive Disorder Drugs Market Outlook
- 6.3.5.1. Market Size & Forecast
- 6.3.5.2. Market Share & Forecast
- 6.3.5.2.1. By Type
- 6.3.5.2.2. By Application
7. Europe Obsessive-Compulsive Disorder Drugs Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Application
- 7.2.3. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Obsessive-Compulsive Disorder Drugs Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Type
- 7.3.1.2.2. By Application
- 7.3.2. Germany Obsessive-Compulsive Disorder Drugs Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Type
- 7.3.2.2.2. By Application
- 7.3.3. Spain Obsessive-Compulsive Disorder Drugs Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Type
- 7.3.3.2.2. By Application
- 7.3.4. Italy Obsessive-Compulsive Disorder Drugs Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Type
- 7.3.4.2.2. By Application
- 7.3.5. United Kingdom Obsessive-Compulsive Disorder Drugs Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Type
- 7.3.5.2.2. By Application
8. North America Obsessive-Compulsive Disorder Drugs Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Application
- 8.2.3. By Country
- 8.3. North America: Country Analysis
- 8.3.1. United States Obsessive-Compulsive Disorder Drugs Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Type
- 8.3.1.2.2. By Application
- 8.3.2. Mexico Obsessive-Compulsive Disorder Drugs Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Type
- 8.3.2.2.2. By Application
- 8.3.3. Canada Obsessive-Compulsive Disorder Drugs Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Type
- 8.3.3.2.2. By Application
9. South America Obsessive-Compulsive Disorder Drugs Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Application
- 9.2.3. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Obsessive-Compulsive Disorder Drugs Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Type
- 9.3.1.2.2. By Application
- 9.3.2. Argentina Obsessive-Compulsive Disorder Drugs Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Type
- 9.3.2.2.2. By Application
- 9.3.3. Colombia Obsessive-Compulsive Disorder Drugs Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Type
- 9.3.3.2.2. By Application
10. Middle East and Africa Obsessive-Compulsive Disorder Drugs Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Application
- 10.2.3. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Obsessive-Compulsive Disorder Drugs Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Type
- 10.3.1.2.2. By Application
- 10.3.2. Saudi Arabia Obsessive-Compulsive Disorder Drugs Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Type
- 10.3.2.2.2. By Application
- 10.3.3. UAE Obsessive-Compulsive Disorder Drugs Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Type
- 10.3.3.2.2. By Application
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. Global Obsessive-Compulsive Disorder Drugs Market: SWOT Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Product
15. PESTLE Analysis
16. Competitive Landscape
- 16.1. Abbott SA
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (In case of listed companies)
- 16.1.5. Recent Developments
- 16.1.6. SWOT Analysis
- 16.2. Eli Lilly, and Company
- 16.2.1. Business Overview
- 16.2.2. Company Snapshot
- 16.2.3. Products & Services
- 16.2.4. Financials (In case of listed companies)
- 16.2.5. Recent Developments
- 16.2.6. SWOT Analysis
- 16.3. Viatria Inc.,
- 16.3.1. Business Overview
- 16.3.2. Company Snapshot
- 16.3.3. Products & Services
- 16.3.4. Financials (In case of listed companies)
- 16.3.5. Recent Developments
- 16.3.6. SWOT Analysis
- 16.4. H. LUNDBECK A/S
- 16.4.1. Business Overview
- 16.4.2. Company Snapshot
- 16.4.3. Products & Services
- 16.4.4. Financials (In case of listed companies)
- 16.4.5. Recent Developments
- 16.4.6. SWOT Analysis
- 16.5. GlaxoSmithKline plc
- 16.5.1. Business Overview
- 16.5.2. Company Snapshot
- 16.5.3. Products & Services
- 16.5.4. Financials (In case of listed companies)
- 16.5.5. Recent Developments
- 16.5.6. SWOT Analysis
- 16.6. Pfizer Inc.
- 16.6.1. Business Overview
- 16.6.2. Company Snapshot
- 16.6.3. Products & Services
- 16.6.4. Financials (In case of listed companies)
- 16.6.5. Recent Developments
- 16.6.6. SWOT Analysis
- 16.7. Zydus Pharmaceuticals, Inc.
- 16.7.1. Business Overview
- 16.7.2. Company Snapshot
- 16.7.3. Products & Services
- 16.7.4. Financials (In case of listed companies)
- 16.7.5. Recent Developments
- 16.7.6. SWOT Analysis
- 16.8. Lupin Pharmaceuticals, Inc.,
- 16.8.1. Business Overview
- 16.8.2. Company Snapshot
- 16.8.3. Products & Services
- 16.8.4. Financials (In case of listed companies)
- 16.8.5. Recent Developments
- 16.8.6. SWOT Analysis
- 16.9. Amneal Pharmaceuticals LLC.
- 16.9.1. Business Overview
- 16.9.2. Company Snapshot
- 16.9.3. Products & Services
- 16.9.4. Financials (In case of listed companies)
- 16.9.5. Recent Developments
- 16.9.6. SWOT Analysis
- 16.10.Teva Pharmaceutical industries Ltd.
- 16.10.1. Business Overview
- 16.10.2. Company Snapshot
- 16.10.3. Products & Services
- 16.10.4. Financials (In case of listed companies)
- 16.10.5. Recent Developments
- 16.10.6. SWOT Analysis
17. Strategic Recommendations
18. About Us & Disclaimer
